Nuwellis, Inc. (NASDAQ: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company’s common stock at a price of $2.59 per share of common stock in a registered direct offering priced at-the-market under NASDAQ rules.
Nuwellis also received approximately $3.1 Million in gross proceeds from the exercise of previously issued warrants which were issued in connection with the Company’s June 2026 public offering.
In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 1,310,890 shares of common stock.
This morning’s news release goes on to say the warrants have an exercise price of $2.59 per share, will be exercisable immediately following the date of issuance and will have a term of five years from the date of effectiveness of the registration statement for the purposes of registering the shares of common stock underlying the warrants.
The closing of the registered direct offering and the concurrent private placement is expected to occur on or about August 3, 2026, subject to the satisfaction of customary closing conditions.
NUWE shares slumped $2.75, or 61.8%, to $1.70.
